Abstract

Despite being a highly successful chemotherapeutic drug, doxorubicin (DOX) has several significant disadvantages. Therefore, there is a drive to create novel medication combinations and different modes of delivery of the anticancer drug. Here, we outline a strategy for DOX photorelease, utilizing a photolabile precursor ruthenium complex [Ru(bpy)2Cl2] 1 to develop the light-activated prodrug [Ru(bpy)2DOX](PF6)22. The DOX complex is stable in the dark but releases DOX when exposed to visible light.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call